10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RAT IgG1 isotype control Biotin

Monoclonal IgG1 , Biotin
Catalog # ASR1131

Product Information

Description	RAT IgG1 isotype control Biotin conjugated
Conjugate	Biotin
FP Value	2-8 moles Biotin per mole of Rat IgG1
Clonality	Monoclonal IgG1
Physical State	Liquid (sterile filtered)
Host Isotype	IgG1
Species of Origin	Rat
Stabilizer	None
Preservative	0.01% (w/v) Sodium Azide

Additional Information

Shipping Condition	Wet Ice
Application Note	RAT IgG1 isotype control can be utilized as a control or standard reagent in Western Blotting, Flow Cytometry, and ELISA experiments where determination of sample isotype is important. Specific conditions should be optimized by user.
Purity	RAT IgG1 isotype control has been prepared from concentrated cell culture supernatant by immunoaffinity chromatography using protein G. In an Ouchterlony double diffusion assay the material is non-reactive with antisera to rat IgG2a, IgG2b, IgG3 , IgM , and IgA. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Rat IgG and anti-Rat serum. Light and heavy chain composition has been confirmed.
Storage Condition	Store vial at 4° C prior to opening. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use. DO NOT FREEZE. This product is light sensitive.
Precautions Note	This product is for research use only and is not intended for therapeutic or diagnostic applications.

Background

RAT IgG1 isotype control is used in flow cytometry, western blot and ELISA and differentiate between immunoglobulin classes and subclasses. Isotype controls allow for the genetic variations or differences in the constant regions of the heavy and light chains. In Rat there are six relevant heavy chain isotypes and two light chain isotypes: heavy chain a - IgA, ? - IgG 1, 2a, 2b, 2c and □- IgM, light chain ? and ?.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.